This paper lays the foundation for use of DPSCs in the treatment of corneal (eye) damage.
Dental pulp stem cells (DPSCs) have the ability to differentiate into neurons for potential use in the treatment of neurological disorders involving a decline in cognitive abilities in humans.
Mesenchymal stem cells (MSCs) show promise as a safe and effective therapeutic agent in the treatment of liver cirrhosis.
Mesenchymal stem cell expression of interleukin-35 protects against ulcerative colitis by suppressing mucosal immune responses.
An allogeneic ‘off the shelf’ therapeutic strategy for peripheral nerve tissue engineering using clinical grade human neural stem cells
Mesenchymal stem cell-derived exosomes ameliorate erection by reducing oxidative stress damage of corpus cavernosum in a rat model of artery injury.
The dental pulp stem cells (DPSCs) from younger stem cell donors are more effective at tissue repair than those from older donors, providing further evidence of the importance of banking stem cells while young.
In rodents, mesenchymal stem cells (MSCs) applied topically to the brain have the potential to improve neurological function after damage similar to a stroke (cerebral ischemia).